scholarly journals Lifitegrast Ophthalmic Solution – A Review

2021 ◽  
pp. 186-188
Author(s):  
S. Padmaja ◽  
K. Lakshitha Niyatee Rao
Keyword(s):  
Dry Eye ◽  
Ophthalmic Solution ◽  
Review Article ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Data Bases ◽  
Dry Eyes ◽  
Safety And Efficacy ◽  
Search Terms

Introduction: In this review article the safety and efficacy of of Lifitegrast™ in the management of dry eye disease is described. Methods: Search was carried out using related search terms in data bases like pubmed and related articles were referred. Result: A larger reduction in Eye dryness Score (EDS) was seen with Lifitegrast™. Conclusion: Lifitegrast™ ophthalmic solution 5% provides a new option for the treatment of dry eyes.

Safety and efficacy of ALG-1007 topical ophthalmic solution – A synthetic peptide that regulates inflammation, in patients with dry eye disease: An exploratory Phase I, open-label, single-center clinical study

2020 ◽  
Vol 3 ◽  
pp. 10
Author(s):  
Richard Lindstrom ◽  
Eric Donnenfeld ◽  
Edward Holland ◽  
Vicken Karageozian ◽  
John Park ◽  
...  
Keyword(s):  
Phase I ◽  
Dry Eye ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Multiple Time ◽  
Open Label ◽  
Safety And Efficacy ◽  
Treatment Groups ◽  
Staining Score

Objectives: The objective of the study was to evaluate the safety and efficacy of ALG-1007 topical ophthalmic solution in patients with dry eye disease (DED). Materials and Methods: This Phase I, prospective, open-label, 12-week study enrolled subjects ≥18 years old with symptoms of DED for at least 6 months and at least one of the following: Total ocular staining score ≥2 or tear film breakup time (TBUT) ≤7 s. Subjects were randomized to four treatment arms: 0.125%, 0.25%, 0.4%, and 0.6% ALG-1007. Subjects received the test drug, 1 drop twice daily, and were followed at multiple time points for 12 weeks. SICCA total ocular staining score, corneal and conjunctival staining score, TBUT, and subject-reported symptoms using the visual analog scale (VAS) symptom index were assessed at baseline and at every visit. The primary safety outcome was percentage and severity of adverse events (AEs). Results: Forty eyes (21 patients) were assigned randomly to four treatment groups (n = 10 per group). Improvement in TBUT, SICCA, and VAS was seen in all groups. The highest dose tested (0.6%) was compared to the lowest dose tested (0.125%) based on change from baseline for all assessments using analysis of variance. Improvement was significantly greater in 0.6% treatment group in terms of TBUT, conjunctiva staining, SICCA, burning, discomfort, photophobia, and the composite symptom score. No serious AEs were reported after 12 weeks of treatment. Conclusion: Outcome measures improved in all the treatment groups. At the highest dose, ALG-1007 demonstrated statistically significant improvement compared to the lowest dose in 7 out of 12 assessments, indicating a dose response. This suggests that the active pharmaceutical ingredient in ALG-1007 is effective in improving signs and symptoms of DED. ALG-1007 was well-tolerated with minimal instillation discomfort and no reported serious AEs.

scholarly journals Defining the needs and preferences of patients with dry eye disease

2019 ◽  
Vol 4 (1) ◽  
pp. e000315
Author(s):  
Penny Asbell ◽  
Elisabeth Messmer ◽  
Colin Chan ◽  
Gary Johnson ◽  
Brigitte Sloesen ◽  
...  
Keyword(s):  
Dry Eye ◽  
Treatment Effectiveness ◽  
Visual Disturbance ◽  
Dry Eye Disease ◽  
Phone Call ◽  
Eye Disease ◽  
Online Questionnaire ◽  
Dry Eyes ◽  
Substantial Impact ◽  
Emerging Trends

ObjectiveDry eye disease is a multifactorial chronic disease, leading to ocular discomfort and visual disturbance with a substantial impact on quality of life. Therefore, the patient’s perspective should be taken into account early in the drug development process. We have developed a step-by-step methodology based on the self-explicated conjoint approach to assess the needs and preferences of patients with moderate-to-severe dry eye disease.Methods and AnalysisFollowing a literature review and social media listening (step 0), qualitative phone call interviews were conducted with 12 patients (step 1). Patients’ responses underwent content analysis and were coded, quantified and displayed as charts. Based on the emerging trends and attributes identified as relevant in steps 0 and 1, a quantitative online questionnaire was designed and conducted with 160 patients across four countries (step 2).ResultsThe online questionnaire was rated as easy/very easy to understand by 60% of respondents, 62% rated the survey as easy/very easy to complete and 71% rated it as interesting/very interesting. Treatment satisfaction was the most important aspect for patients, and the three most relevant attributes were as follows (with the most important indexed to 100%): ‘treatment effectiveness on symptoms of dry eyes’ (100%), ‘frequency of treatment use’ (96%) and ‘how the treatment works’ (95%).ConclusionOur methodology was well received by patients, and the results will help inform future clinical trial development and discussions with health technology assessment bodies and regulators on unmet needs and product attributes that are of most value to patients with dry eye disease.

scholarly journals Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease

2019 ◽  
Vol Volume 13 ◽  
pp. 887-894 ◽  
Author(s):  
Elizabeth Yeu ◽  
Damien F Goldberg ◽  
Francis S Mah ◽  
Kenneth A Beckman ◽  
Jodi I Luchs ◽  
...  
Keyword(s):  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Safety And Efficacy

scholarly journals New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study

2020 ◽  
Vol 37 (4) ◽  
pp. 1664-1674 ◽  
Author(s):  
Paolo Fogagnolo ◽  
Eleonora Favuzza ◽  
Daniele Marchina ◽  
Michela Cennamo ◽  
Roberto Vignapiano ◽  
...  
Keyword(s):  
Prospective Study ◽  
Cataract Surgery ◽  
Dry Eye ◽  
Therapeutic Strategy ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease

scholarly journals Characteristics and Utility of Fluorescein Breakup Patterns among Dry Eyes in Clinic-Based Settings

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 711
Author(s):  
Chika Shigeyasu ◽  
Masakazu Yamada ◽  
Norihiko Yokoi ◽  
Motoko Kawashima ◽  
Kazuhisa Suwaki ◽  
...  
Keyword(s):  
Diagnostic Test ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Subjective Symptoms ◽  
Clinical Tool ◽  
Likelihood Ratios ◽  
Dry Eyes ◽  
Post Test ◽  
Breakup Time

(1) Background: To evaluate the characteristics of fluorescein breakup patterns (FBUPs) among patients with dry eye disease (DED) and efficacy of FBUPs as a diagnostic test for DED subgroups. (2) Methods: The study enrolled 449 patients with DED. FBUPs were categorized as follows: area break (AB), line break (LB), spot break (SB), dimple break (DB), and random break (RB). Schirmer value, fluorescein breakup time (FBUT), keratoconjunctival score, DED subgroups and subjective symptoms were examined. (3) Results: LB patients presented with short FBUT and high keratoconjunctival score. AB patients presented with short FBUT, high cornea and keratoconjunctival scores. SB patients were young with short FBUT. DB patients exhibited low keratoconjunctival score. RB patients were young, with long FBUT and low keratoconjunctival scores. Among DED subgroups, LB and AB constituted 74.7% of aqueous-deficiency dry eye (ADDE). SB and DB constituted 42.4% of short FBUT dry eye (short FBUT-DE). Post-test probabilities and positive likelihood ratios for ADDE were 58.7% and 1.63, respectively; those for short FBUT-DE were 46.3% and 2.02, respectively. Patients with SB and AB exhibited significantly severe subjective symptoms than other FBUPs. (4) Conclusions: FBUPs are associated with both objective findings and symptoms of DED and may be a clinical tool for identification of DED subgroups.

Sign in / Sign up

Export Citation Format

Share Document